OA03.01 A Non-Randomized, Open-Label, Prospective, Multicenter Study of Apatinib as Second-Line and Later-Line Therapy in Patients with ES-SCLCXi Peng, Junying Xu, Yadan Xu et al.|Journal of Thoracic Oncology|2019Cited by 2